ALLMedicine™ Plaque Psoriasis Center

Apr 8th, 2021 - Guselkumab is an IL-23 inhibitor that binds to the p19 subunit of IL-23 that is highly efficacious and well tolerated for the treatment of moderate-to-severe plaque psoriasis. We report a 20-year-old male who developed sensorimotor axonal polyneur...

Mar 31st, 2021 - Plaque psoriasis (PSO) is a common clinical chronic inflammatory skin disease. The incidence rate is increasing year by year due to the fast pace of work and unhealthy diet. Fire needle has been widely used in the treatment of PSO. However, the ef...

Mar 22nd, 2021 - Introduction: Psoriasis is an inflammatory skin disease affecting approximately 3.2% of adults in the United States. The mainstay treatment for mild-to-moderate plaque psoriasis (the most common subtype and severity) is topical therapy.Areas cover...

Mar 20th, 2021 - Psoriasis is a chronic inflammatory skin disease with immune-mediated mechanism. Endocan is a soluble dermatan sulfate proteoglycan expressed by endothelium of blood vessels. The present study aims to evaluate immunohistochemical localization of e...

Mar 15th, 2021 - The current study aims at evaluating the role of circulating or cell-free long noncoding ribonucleic acid (lncRNA) growth arrest-specific 5 (GAS5) in plaque psoriasis and at investigating its relationship with the presented clinical data. This cas...

Jan 6th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Jul 13th, 2020 - Psoriasis is an autoimmune, chronic disease determined by environmental and genetic factors. The occurrence of psoriasis is accompanied by metabolic diseases, cardiovascular diseases (CVD) and depression, disturbances on interpersonal interactions...

Feb 29th, 2020 - Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients’ quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthriti...

Feb 24th, 2020 - Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic plaques on the skin. Psoriasis is frequently associated to comorbidities, including psoriatic arthritis, cardiovascul...

Feb 4th, 2020 - In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline. A meta-analysis o...

Apr 8th, 2021 - Guselkumab is an IL-23 inhibitor that binds to the p19 subunit of IL-23 that is highly efficacious and well tolerated for the treatment of moderate-to-severe plaque psoriasis. We report a 20-year-old male who developed sensorimotor axonal polyneur...

Apr 4th, 2021 - Calcipotriene cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

Mar 31st, 2021 - Plaque psoriasis (PSO) is a common clinical chronic inflammatory skin disease. The incidence rate is increasing year by year due to the fast pace of work and unhealthy diet. Fire needle has been widely used in the treatment of PSO. However, the ef...

Mar 28th, 2021 - Long-term proactive topical management of plaque psoriasis with twice-weekly calcipotriene/betamethasone dipropionate foam has been shown in a high-quality randomized trial to be more effective than conventional reactive management – but will pati...

Mar 22nd, 2021 - Introduction: Psoriasis is an inflammatory skin disease affecting approximately 3.2% of adults in the United States. The mainstay treatment for mild-to-moderate plaque psoriasis (the most common subtype and severity) is topical therapy.Areas cover...

Mar 28th, 2021 - Long-term proactive topical management of plaque psoriasis with twice-weekly calcipotriene/betamethasone dipropionate foam has been shown in a high-quality randomized trial to be more effective than conventional reactive management – but will pati...

Mar 11th, 2021 - (Reuters Health) - For moderate to severe plaque psoriasis, a new study suggests that anti-IL-23 agents have the lowest rates of adverse events, and risankizumab has the best long-term risk-benefit profile. Researchers examined data from 52 random...

Feb 28th, 2021 - Guidelines on the management and treatment of psoriasis with topical and alternative therapies, nonbiologic therapies, phototherapy, and biologic therapies were published in February 2021 by the American Academy of Dermatology and the National Pso...

Nov 5th, 2020 - Tapinarof cream 1% applied once daily in patients with plaque psoriasis convincingly hit its primary and secondary endpoints and was well tolerated in two identical pivotal phase 3, randomized trials, Mark G. Lebwohl, MD, reported at the virtual a...

Oct 28th, 2020 - Discussion Herpes simplex virus infection can affect almost any area of the skin or mucous membranes and presents with localized blistering. Isolation of the virus in tissue culture confirms the diagnosis.[1] In this case, the viral and bacterial ...